

Application No.: 10/729,571
Amendment Dated: 05/21/2007
Reply to Office Action of: 12/21/2006

Remarks/Arguments:

The present response is filed in regard to the Supplemental Requirement for Restriction mailed 12/21/2006 in connection with the above-identified patent application. In response to the Supplemental Restriction Requirement, Applicants elect Group I with traverse.

Groups I, II and III overlap in scope – they relate to crystal structures of a particular *Helicobacter pylori* glutamate racemase (MurI) complexed with glutamate substrate, or glutamate substrate and an inhibitor. There is therefore a structural relationship between the different groups and as such a search of the different crystal forms would not place an undue burden on the Examiner. Applicants request reconsideration.

Sequence compliance

A substitute sequence listing has been filed herewith to replace the existing sequence listing. The substitute sequence listing encompasses all nucleotide and amino acid sequences disclosed in the present application.

Conclusion

The above amendments have been made without prejudice to Applicants right to prosecute any cancelled subject matter in a timely filed continuation application.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

A petition for a four month extension of time is being filed herewith, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100966-2P US.

Application No.: 10/729,571
Amendment Dated: 05/21/2007
Reply to Office Action of: 12/21/2006

Although Applicants believe no other fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100966-2P US.

Respectfully submitted,

/Christine McCormack/

Name: Christine McCormack
Dated: 05/21/2007
Reg. No.: L0065
Phone No.: 781 839 4693
Global Intellectual Property, Patents,
AstraZeneca R&D Boston,
35, Gatehouse Drive, Waltham, MA 02451